In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis
Pharmaceutics · 06.04.2023 · 15 (4) · 1163
DOI: 10.3390/pharmaceutics15041163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 06.04.2023. Verfasst von Lucía Román-Álamo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Rosselló 149-153, 08036 Barcelona, Spain. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Fundació La Marató de TV3, Generalitat de Catalunya, Spain.
Abstract (Originalsprache)
The second-line antileishmanial compound pentamidine is administered intramuscularly or, preferably, by intravenous infusion, with its use limited by severe adverse effects, including diabetes, severe hypoglycemia, myocarditis and renal toxicity. We sought to test the potential of phospholipid vesicles to improve the patient compliance and efficacy of this drug for the treatment of leishmaniasis by means of aerosol therapy. The targeting to macrophages of pentamidine-loaded liposomes coated with chondroitin sulfate or heparin increased about twofold (up to ca. 90%) relative to noncoated liposomes. The encapsulation of pentamidine in liposomes ameliorated its activity on the amastigote and promastigote forms of Leishmania infantum and Leishmania pifanoi, and it significantly reduced cytotoxicity on human umbilical endothelial cells, for which the concentration inhibiting 50% of cell viability was 144.2 ± 12.7 µM for pentamidine-containing heparin-coated liposomes vs. 59.3 ± 4.9 µM for free pentamidine. The deposition of liposome dispersions after nebulization was evaluated with the Next Generation Impactor, which mimics human airways. Approximately 53% of total initial pentamidine in solution reached the deeper stages of the impactor, with a median aerodynamic diameter of ~2.8 µm, supporting a partial deposition on the lung alveoli. Upon loading pentamidine in phospholipid vesicles, its deposition in the deeper stages significantly increased up to ~68%, and the median aerodynamic diameter decreased to a range between 1.4 and 1.8 µm, suggesting a better aptitude to reach the deeper lung airways in higher amounts. In all, nebulization of liposome-encapsulated pentamidine improved the bioavailability of this neglected drug by a patient-friendly delivery route amenable to self-administration, paving the way for the treatment of leishmaniasis and other infections where pentamidine is active.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Rosselló 149-153, 08036 Barcelona, Spain.
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, 08028 Barcelona, Spain.
- Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain.
- Department of Life and Environmental Sciences, University of Cagliari, University Campus, S.P. Monserrato-Sestu Km 0.700, 09042 Monserrato, Italy.
- Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain.
- Group of Recycling and Valorization of Waste Materials (REVAL), Marine Research Institute (IIM-CSIC), Eduardo Cabello 6, 36208 Vigo, Spain.
ORCID-Profile: Mohamad Allaw, Yunuen Avalos-Padilla, Maria Letizia Manca, Maria Manconi, Federica Fulgheri, Luis Rivas, José Antonio Vázquez, Xavier Roca-Geronès, Maria Magdalena Alcover, Roser Fisa, Cristina Riera, Xavier Fernàndez-Busquets
Förderung
- Wellcome Trust
- Fundació La Marató de TV3
- Generalitat de Catalunya, Spain
- MCIN Subdirección General de Redes y Centros de Investigación Cooperativa-FEDER
- CSIC
Zitieren
APA
Román-Álamo, L., Allaw, M., Avalos-Padilla, Y., Manca, M. L., Manconi, M., Fulgheri, F., Fernández-Lajo, J., Rivas, L., Vázquez, J. A., Peris, J. E., Roca-Geronès, X., Poonlaphdecha, S., Alcover, M. M., Fisa, R., Riera, C., & Fernàndez-Busquets, X. (2023). In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis. Pharmaceutics, 15(4), 1163. https://doi.org/10.3390/pharmaceutics15041163
Vancouver
Román-Álamo L, Allaw M, Avalos-Padilla Y, Manca ML, Manconi M, Fulgheri F, et al. In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis. Pharmaceutics. 2023;15(4):1163. doi:10.3390/pharmaceutics15041163
BibTeX
@article{Romnlamo2023,
author = {Román-Álamo, Lucía and Allaw, Mohamad and Avalos-Padilla, Yunuen and Manca, Maria Letizia and Manconi, Maria and Fulgheri, Federica and Fernández-Lajo, Jorge and Rivas, Luis and Vázquez, José Antonio and Peris, José Esteban and Roca-Geronès, Xavier and Poonlaphdecha, Srisupaph and Alcover, Maria Magdalena and Fisa, Roser and Riera, Cristina and Fernàndez-Busquets, Xavier},
title = {In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {4},
pages = {1163},
doi = {10.3390/pharmaceutics15041163}
}
EUVIMED